Please assess the completion status of the following clinical trial:

Trial Title: CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥16 years old (\>18 years of age in the United States)~* Admitted to hospital with confirmed COVID-19 respiratory illness~* Receiving supplemental oxygen~* 500 mL of ABO compatible convalescent plasma is available~Exclusion Criteria:~* Onset of respiratory symptoms \>12 days prior to randomization~* Intubated or plan in place for intubation~* Plasma is contraindicated (e.g. history of anaphylaxis from transfusion)~* Decision in place for no active treatment

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent plasma (Type: EXPERIMENTAL): \~500 mL ABO compatible convalescent apheresis plasma
- Standard of care (Type: NO_INTERVENTION): Treated as per institutional standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).